Operationally generated. First-party. Consent-based. Refreshed daily. The largest exclusive condition-confirmed cohort in healthcare.
Every record in Summit's data layer was generated operationally — by companies that ran real patient acquisition campaigns across real conditions for a decade. This is not a data purchase, a claims append, or a probabilistic model. It is the output of live campaign operations.
Every patient self-identified by completing an intake form, calling a call center, or engaging with an unbranded landing page on a condition-specific campaign. Zero records sourced from third-party data exchanges, list purchases, or public records.
Summit's data layer refreshes against real pharmacy fulfillment events — not modeled behavior, not prescription claims, not inferred adherence. 1,008,348 Rx events on file across the T1 cohort. Data is current, not historical.
Summit's patient data is organized in four tiers, each representing a distinct level of patient qualification and commercial utility. The tiers are cumulative — the dataset is one cohort, segmented by how far each patient progressed through the acquisition funnel.
Patients who completed an intake form on an unbranded campaign and confirmed a condition. First-party. Consent-based. Intent signal confirmed. The broadest tier and the primary targeting audience for new patient acquisition.
Patients whose intake responses or health assessment indicated a healthcare provider diagnosis on the target condition. Provider-confirmed diagnosis, not self-reported. Used for HCP-informed targeting and access program activation.
Patients with a fill-verified prescription on file for the target condition. Confirmed treatment, not inferred prescription. Full Rx history available. Supply cadence on file. The attribution layer — T3 → T1 match proves campaign effectiveness.
Prescriber records linked to confirmed patient volume across the cohort. NPI-level specialty, state, and prescribing activity — not cold specialty codes. HCPs in this layer have diagnosed or prescribed to Summit patients in the condition pathways.
Every record in the 15.3M cohort carries 17 enrichment columns drawn from the Census Bureau's American Community Survey (ACS) 5-year estimates and the CDC's PLACES dataset — giving brands the demographic, socioeconomic, and health context to build precision-targeted audience segments without additional data appends.
Summit's patient acquisition campaigns operated across nine condition pathways simultaneously — each generating its own intake, qualification, and fulfillment data. The dataset reflects the actual clinical diversity of the patient population these campaigns reached.
6,819,000 records · T3 panel + T2 diagnosis cohort + T1 fill-verified sub-cohort. The highest-volume condition pathway in the data layer.
Condition · 022,015,000 records · Condition-confirmed via intake. CPAP device adoption pathway included in T1 sub-cohort.
Condition · 032,100,000 records · Cardiovascular condition pathway. 13.5% AFib sub-cohort in the cardiac cohort. Remote monitoring patient segment included.
Condition · 041,240,000 records · Obesity pathway with GLP-1 Bridge sub-cohort. 19,470 fill-verified GLP-1 patients on supply at last refresh. 85% compound, 45% adherent.
Condition · 05~3.2M records · Multi-condition patients on 5+ chronic medications. Comorbidity index + cross-condition targeting layer.
Condition · 06~2.4M records · Medicare Advantage beneficiaries in the patient cohort. Coverage-expansion trigger events included.
Condition · 07~1.6M records · Chronic pain condition pathway. Adjacent to polypharmacy and diabetes cohorts.
Condition · 08~580,000 records · OAB and stress incontinence patient cohort. Condition-confirmed via intake. Adjacent to cardiac and polypharmacy pathways.
Condition · 09~1.1M records · Asthma and COPD respiratory pathway. Adjacent to sleep apnea and cardiac cohorts.
Summit's data compliance posture is production-ready for pharma brands. HIPAA Safe Harbor de-identification on every record. BAA available to all licensees. SOC 2 Type II audit in progress.
All patient records de-identified per HIPAA Safe Harbor §164.514(b). Expert determination documentation on file. De-identification is the foundational compliance act — every downstream use of the data depends on it.
Summit signs Business Associate Agreements with all licensees. The BAA covers the full data layer and all platform operations that process PHI-adjacent records.
SOC 2 Type II audit in progress. External penetration testing completed Q1 2026. Audit documentation and penetration test results available under NDA.
Summit licenses the data layer to brands, agencies, and holding companies across the full range of commercial structures. The license is scoped per condition, per tier, per geography, per term.
The fastest path is a focused conversation about your target conditions, audience needs, and timeline. We'll scope a license structure and walk through match rates and cohort sizing.
Summit operates as the independent sponsor entity for unbranded campaign work that brand clients cannot run directly. Multi-brand relationships across the full data layer are available.
Summit's data is exclusive. The platform is operational. The protocol is proprietary. We're open to category exclusive, full exclusive, and partnership / rev-share structures depending on what you're building.